| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 190 |
| 1 | NIVOLUMAB | 159 |
| 2 | CARBOPLATIN | 112 |
| 3 | IPILIMUMAB | 104 |
| 4 | DURVALUMAB | 55 |
| 5 | PACLITAXEL | 48 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 46 |
| 7 | DEXAMETHASONE | 39 |
| 8 | DEXAMETHASONE 1.5 MG | 39 |
| 9 | LANSOPRAZOLE | 35 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NAFCILLIN SODIUM | 5 | 0.0054 |
| 1 | VINORELBINE | 30 | 0.0043 |
| 2 | DOSTARLIMAB | 9 | 0.0036 |
| 3 | DURVALUMAB | 55 | 0.0025 |
| 4 | AMIFOSTINE | 2 | 0.0025 |
| 5 | IPILIMUMAB | 104 | 0.0024 |
| 6 | TREMELIMUMAB | 10 | 0.0023 |
| 7 | ENFORTUMAB VEDOTIN | 17 | 0.0022 |
| 8 | PRAZOSIN HYDROCHLORIDE | 3 | 0.0022 |
| 9 | PEMBROLIZUMAB | 190 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 365 |
| 1 | Platinum-based Drug [EPC] | 146 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 113 |
| 3 | Corticosteroid [EPC] | 62 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 58 |
| 5 | Proton Pump Inhibitor [EPC] | 55 |
| 6 | Microtubule Inhibitor [EPC] | 52 |
| 7 | Factor Xa Inhibitor [EPC] | 48 |
| 8 | 5-alpha Reductase Inhibitor [EPC] | 32 |
| 9 | Histamine-2 Receptor Antagonist [EPC] | 31 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 365 | 0.0037 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 58 | 0.0027 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 113 | 0.0023 |
| 3 | Platinum-based Drug [EPC] | 146 | 0.0005 |
| 4 | Isocitrate Dehydrogenase 1 Inhibitor [EPC] | 1 | 0.0005 |
| 5 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 4 | 0.0005 |
| 6 | Cardiac Glycoside [EPC] | 26 | 0.0004 |
| 7 | Microtubule Inhibitor [EPC] | 52 | 0.0003 |
| 8 | 5-alpha Reductase Inhibitor [EPC] | 32 | 0.0003 |
| 9 | Sulfone [EPC] | 3 | 0.0003 |